Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Possible heart failure caused by osimertinib in a lung cancer patient.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Jun 2023

Ruiz-Briones Paula, Escudero-Vilaplana Vicente, Collado-Borrell Roberto, Vicente-Valor Juan, Alvarez Rosa, Villanueva-Bueno Cristina, Narrillos-Moraza Álvaro, Herranz Ana, Sanjurjo Maria

Abstract excerpt

INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC). It has demonstrated better results concerning effectiveness than other TKIs for the same indication. However, despite a good safety profile, it could produce some cardiotoxicity that does not occur with other drugs of the same...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cardiotoxicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Failure

Share to Lung Neoplasms

Share to Mutation

Share to Stroke Volume

Share to Ventricular Function, Left

Source

Identifiers

PMID: 36480925
DOI: 10.1177/10781552221143787

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Possible heart failure caused by osimertinib in a lung cancer patient.PMID 36480925Read ↗

Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.Semantic proximity Read ↗

Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib.Semantic proximity Read ↗

Successful Management of Osimertinib-Induced Heart Failure.Semantic proximity Read ↗

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

[A Case of Significant Ejection Fraction Reduction and Heart Failure Induced by Osimertinib].Semantic proximity Read ↗

Osimertinib- Cardiac Dysfunction with Prolonged QTc Interval: Case ReportSemantic proximity Read ↗

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.Semantic proximity Read ↗

Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib-related Pulmonary Fibrosis, A case report and review of literatureSemantic proximity Read ↗

Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.Semantic proximity Read ↗

Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib.Semantic proximity Read ↗

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.